<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Behav Neurosci</journal-id><journal-id journal-id-type="iso-abbrev">Front Behav Neurosci</journal-id><journal-id journal-id-type="publisher-id">Front. Behav. Neurosci.</journal-id><journal-title-group><journal-title>Frontiers in Behavioral Neuroscience</journal-title></journal-title-group><issn pub-type="epub">1662-5153</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4199258</article-id><article-id pub-id-type="doi">10.3389/fnbeh.2014.00360</article-id><article-categories><subj-group subj-group-type="heading"><subject>Neuroscience</subject><subj-group><subject>Mini Review Article</subject></subj-group></subj-group></article-categories><title-group><article-title>Oxytocin treatment in pediatric populations</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Taylor</surname><given-names>Adrienne E.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="author-notes" rid="fn001"><sup>*</sup></xref><uri xlink:type="simple" xlink:href="http://community.frontiersin.org/people/u/167914"/></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Hsu-en</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Buisman-Pijlman</surname><given-names>Femke T. A.</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><uri xlink:type="simple" xlink:href="http://community.frontiersin.org/people/u/47603"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Department of Psychological Medicine, Women's and Children's Hospital</institution><country>Adelaide, SA, Australia</country></aff><aff id="aff2"><sup>2</sup><institution>School of Medicine, The University of Adelaide</institution><country>Adelaide, SA, Australia</country></aff><aff id="aff3"><sup>3</sup><institution>Discipline of Pharmacology, Faculty of Health Sciences, School of Medical Sciences, The University of Adelaide</institution><country>Adelaide, SA, Australia</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Lisa A. Parr, Emory University, USA</p></fn><fn fn-type="edited-by"><p>Reviewed by: Valery Grinevich, German Cancer Research Center DKFZ and University of Heidelberg, Germany; Bernadette Von Dawans, University of Freiburg, Germany</p></fn><corresp id="fn001">*Correspondence: Adrienne E. Taylor, Department of Psychological Medicine, Women's and Children's Hospital, 72 King William Road, North Adelaide, Adelaide, SA 5006, Australia e-mail: <email xlink:type="simple">adrienne.taylor@health.sa.gov.au</email></corresp><fn fn-type="other" id="fn002"><p>This article was submitted to the journal Frontiers in Behavioral Neuroscience.</p></fn></author-notes><pub-date pub-type="epub"><day>16</day><month>10</month><year>2014</year></pub-date><pub-date pub-type="collection"><year>2014</year></pub-date><volume>8</volume><elocation-id>360</elocation-id><history><date date-type="received"><day>25</day><month>6</month><year>2014</year></date><date date-type="accepted"><day>29</day><month>9</month><year>2014</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2014 Taylor, Lee and Buisman-Pijlman.</copyright-statement><copyright-year>2014</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>The role of endogenous oxytocin as neuromodulator of birth, lactation and social behaviors is well-recognized. Moreover, the use of oxytocin as a facilitator of social and other behaviors is becoming more and more accepted. Many positive effects have been attributed to intranasal oxytocin administration in animals and humans; with current research highlighting encouraging advances in its potential for use in mental health disorders. The new frontier will be investigating the effective use of oxytocin in pediatric populations. Limited animal data is available on this. Large-scale human studies focusing on autism are currently under way, but many other possibilities seem to lie in the future. However, we need to know more about the risks and effects of repeated use on the developing brain and body. This paper will provide an overview of the current understanding of the role of endogenous oxytocin and its related neuropeptide systems in influencing behaviors, in particular attachment, and will review (a) the literature on the use of intranasal oxytocin in young animals, children (age range birth-12 years) and adolescents (age range 13&#x02013;19 years), (b) the expected benefits and risks based on the current research, and (c) the risks of oxytocin in children with severe psychopathology and early life trauma. The paper will conclude with a clinical perspective on these findings.</p></abstract><kwd-group><kwd>oxytocin</kwd><kwd>neuropeptide</kwd><kwd>attachment</kwd><kwd>pediatric populations</kwd><kwd>intranasal oxytocin</kwd></kwd-group><counts><fig-count count="0"/><table-count count="2"/><equation-count count="0"/><ref-count count="60"/><page-count count="8"/><word-count count="6312"/></counts></article-meta></front><body><sec sec-type="introduction" id="s1"><title>Introduction</title><p>Current understanding of oxytocin and its related neuropeptide systems is growing at an exponential rate. Oxytocin's centrally acting role in behavioral modulation and attachment is increasingly recognized (Feldman, <xref rid="B26" ref-type="bibr">2012</xref>; Churchland and Winkielman, <xref rid="B17" ref-type="bibr">2012</xref>; Tops et al., <xref rid="B62" ref-type="bibr">2014</xref>). Recent studies (Broadbear et al., <xref rid="B13" ref-type="bibr">2014</xref>; Love, <xref rid="B43" ref-type="bibr">2014</xref>; Tops et al., <xref rid="B62" ref-type="bibr">2014</xref>) have been able to highlight a neurobiological model for these behavioral changes, and outline with greater specificity the complex interaction between oxytocin and other neuropeptides and monoamines. These findings have been applied and expanded to the field of addiction, and behavioral neuroscience (Kovacs et al., <xref rid="B41" ref-type="bibr">1998</xref>; Rilling et al., <xref rid="B57" ref-type="bibr">2012</xref>; Buisman-Pijlman et al., <xref rid="B15" ref-type="bibr">2014b</xref>; Williams and Johns, <xref rid="B64" ref-type="bibr">2014</xref>; Zanos et al., <xref rid="B65" ref-type="bibr">2014</xref>). Many positive effects have now been attributed to intranasal oxytocin in the adult population (Veening and Olivier, <xref rid="B63" ref-type="bibr">2013</xref>), however there are multiple questions that remain unanswered in regards to the safe and effective use of intranasal oxytocin in the child and adolescent population. In particular, there is a lack of evidence in regards to the effects of both acute and chronic exposure on the developing brain. This paper aims to provide a review of current knowledge in relation to this area, and highlight both theoretical and clinical gaps in research evidence and data regarding what will likely be an increasing area of interest in the management of common childhood and adolescent psychiatric disorders in future.</p><p>This paper will briefly review the current understanding of the role of endogenous oxytocin and its related neuropeptide systems in influencing behaviors, in particular attachment, and will review (a) the literature on the use of intranasal oxytocin in young animals, infants, children and adolescents, (b) the expected benefits and risks based on the current research, and (c) the risks of oxytocin in children with severe psychopathology and early life trauma. Finally this paper aims to utilize the current knowledge base to assist in providing a framework for the direction of potential further clinical application and will provide examples for future research questions.</p></sec><sec><title>Oxytocin and its related neuropeptide systems</title><p>Oxytocin, a hormone synthesized by the hypothalamus and subsequently secreted by the posterior pituitary gland, is a neuropeptide well-known for its neuro-modulatory role in lactation, child-birth, mother-infant bonding (Love, <xref rid="B43" ref-type="bibr">2014</xref>), and more recently for its role in social affiliation and partner attachment in adults (Buisman-Pijlman et al., <xref rid="B15" ref-type="bibr">2014b</xref>; Tops et al., <xref rid="B62" ref-type="bibr">2014</xref>). Oxytocin's centrally acting effects form the basis of research stemming from Nobel laureate in Chemistry Vincent du Vigneaud's early descriptions and syntheses of oxytocin and vasopressin in 1953 (Love, <xref rid="B43" ref-type="bibr">2014</xref>; Sarnyai and Kovacs, <xref rid="B58" ref-type="bibr">2014</xref>). Oxytocin has it's effect through the Oxytocin receptor and Vasopressin 1A Receptor. Immunohistochemical studies have revealed that magnocellular oxytocin neurons of paraventricular, supraoptic, and accessory hypothalamic nuclei via local dendritic and distant axonal release of oxytocin modulate various forms of behaviors (Lee et al., <xref rid="B42" ref-type="bibr">2009</xref>; Knobloch et al., <xref rid="B40" ref-type="bibr">2012</xref>; Dolen et al., <xref rid="B22" ref-type="bibr">2013</xref>). It is possible that axonal projections of oxytocin neurons can be altered in patients afflicted with neurodevelopmental diseases, which may impair oxytocin signaling and contribute to defects in social behavior. Such pathophysiological mechanisms require further research.</p><p>Oxytocin has been shown to have a relationship with both vasopressin and serotonergic neural pathways (Broadbear et al., <xref rid="B13" ref-type="bibr">2014</xref>), with increasing evidence suggesting that oxytocin and vasopressin's individual and combined modulatory influences on related neurotransmitter systems, including dopaminergic, serotonergic, and endogenous opioid system play a crucial role in the brain's motivational and reward pathways (Love, <xref rid="B43" ref-type="bibr">2014</xref>), and behaviors related to stress-responses and addiction (Buisman-Pijlman et al., <xref rid="B15" ref-type="bibr">2014b</xref>; Tops et al., <xref rid="B62" ref-type="bibr">2014</xref>). Oxytocin has also been implicated in modulating the reactivity of the hypothalamic-pituitary-adrenal axis (Buisman-Pijlman et al., <xref rid="B15" ref-type="bibr">2014b</xref>), thus in part determining the extent of psychological and physiological response to stress (Feldman, <xref rid="B26" ref-type="bibr">2012</xref>).</p><p>This expanding knowledge base has underpinned adult human and animal studies administrating intranasal oxytocin as a modulator of behaviors, for example, those associated with substance abuse (McGregor and Bowen, <xref rid="B44" ref-type="bibr">2012</xref>; Pedersen et al., <xref rid="B53" ref-type="bibr">2013</xref>). Authors have outlined the rationale for intranasal administration of oxytocin in research, based on this administration route bypassing the blood-brain barrier, and increasing the half-life of the delivered substance in cerebrospinal fluid thus ensuring maximization of centrally acting effects (Veening and Olivier, <xref rid="B63" ref-type="bibr">2013</xref>). Intranasal delivery accesses rostral and possibly other brain areas following absorption through the nasal epithelium (Veening and Olivier, <xref rid="B63" ref-type="bibr">2013</xref>). In the pediatric population, intranasal delivery of oxytocin is likely to be the easiest, least intrusive and most preferable mode of administration given pragmatic factors relating to level of insight into treatment, and aversion behaviors, however this needs further investigation.</p><p>From a clinical perspective, Intellectual Disabilities, Autism Spectrum Disorders (ASDs) and ADHD are common neurodevelopmental disorders presenting in childhood. Whilst neurodevelopmental disorders frequently require ongoing treatment and management in adolescent populations, this is an age group in which affective disorders, anxiety disorders and eating disorders, or traits thereof, also start to manifest and may require clinical intervention. In the child and adolescent this cohort, disorders are frequently and universally, however not exclusively, underpinned by a developmental history characterized by attachment difficulties or early life trauma.</p></sec><sec><title>Oxytocin's role in attachment</title><p>An important precursor to the investigation of oxytocin's role within pediatric populations is the concept of attachment. From a theoretical perspective, Bowlby defines attachment as &#x0201c;<italic>a biological instinct&#x02026;Attachment behavior anticipates a response by the attachment figure which will remove threat or discomfort</italic>&#x0201d; (Bowlby, <xref rid="B12" ref-type="bibr">1960</xref>). Oxytocin has been implicated in priming the bond between a mother and child (Love, <xref rid="B43" ref-type="bibr">2014</xref>), and it is known from animal studies that the development of the oxytocin system continues throughout the postnatal period in an experience-dependent manner (Oreland et al., <xref rid="B51" ref-type="bibr">2010</xref>). Given that development of secure attachment is in part reliant on an infant's salience toward their primary caregiver, evidence that administration of oxytocin improves the salience of social cues further highlights the importance of oxytocin in the process of attachment (Love, <xref rid="B43" ref-type="bibr">2014</xref>; Tops et al., <xref rid="B62" ref-type="bibr">2014</xref>).</p></sec><sec><title>Variations in the oxytocin system</title><p>Notably, findings from animal and human studies display that there are individual variations within basal oxytocin levels and in reactivity of the system. Whilst genetics contribute in part, environmental influences such as social experiences, stress and trauma early in life have also been shown to affect this variation. Buisman-Pijlman et al. (<xref rid="B15" ref-type="bibr">2014b</xref>) outlined that these influences can induce long-term changes to the oxytocin system, having a subsequent impact on an individual's susceptibility to addiction and relapse. Feldman (<xref rid="B26" ref-type="bibr">2012</xref>) also noted that the human oxytocin system is sensitive to both positive early social experiences and negative experiences such as separation. Rather than a static feedback system, it is now more accepted through recent studies that the human oxytocin system functions in a complex context-dependent manner (Feldman, <xref rid="B26" ref-type="bibr">2012</xref>; Guastella and Macleod, <xref rid="B32" ref-type="bibr">2012</xref>). Factors aside from genetic influence that have been implicated in variations in an individual's oxytocin system include prenatal maternal stress and substance use (Johns et al., <xref rid="B38" ref-type="bibr">1998</xref>), early life trauma including parental separation (Opacka-Juffry and Mohiyeddini, <xref rid="B50" ref-type="bibr">2012</xref>), and childhood sexual abuse (Heim et al., <xref rid="B34" ref-type="bibr">2009</xref>). A sound understanding of these factors will be of importance to assess the risks and benefits of exogenous oxytocin in the pediatric population.</p></sec><sec><title>Current evidence on the use of intranasal oxytocin in young animals, infants, children, and adolescents</title><p>In the adult population, literature on the use of intranasal oxytocin has spanned the last six decades in research, with early reports focusing on its role in obstetrics (Hendricks and Pose, <xref rid="B36" ref-type="bibr">1961</xref>; Cohen et al., <xref rid="B18" ref-type="bibr">1962</xref>), followed by exploration of oxytocin's possible application to the field of psychiatry, in particular, obsessive compulsive disorder (Ansseau et al., <xref rid="B1" ref-type="bibr">1987</xref>; Den Boer and Westenberg, <xref rid="B21" ref-type="bibr">1992</xref>) and symptoms of post-traumatic stress disorder (Pitman et al., <xref rid="B54" ref-type="bibr">1993</xref>; Olff, <xref rid="B48" ref-type="bibr">2012</xref>).</p><p>In the last 10 years, authors have highlighted oxytocin's prosocial effects in the adult population, categorized further into &#x0201c;trust&#x0201d; (Baumgartner et al., <xref rid="B9" ref-type="bibr">2008</xref>), &#x0201c;mind-reading&#x0201d; and &#x0201c;face-processing and memory&#x0201d; (Heinrichs et al., <xref rid="B35" ref-type="bibr">2003</xref>; Beetz et al., <xref rid="B10" ref-type="bibr">2012</xref>) and stress-response in animals (Parker et al., <xref rid="B52" ref-type="bibr">2005</xref>). It is these benefits, in addition to genetic studies displaying a consistent pattern of oxytocin involvement in ASDs (Campbell et al., <xref rid="B16" ref-type="bibr">2011</xref>), that have led to an interest in the promise of treatment of ASDs with intranasal oxytocin. A recent systematic review of randomized control trials of oxytocin intervention in autism by Preti et al., noted that whilst promising findings in the measures of emotion recognition and eye gaze, there is need for better powered studies prior to valid clinical recommendations being made (Preti et al., <xref rid="B55" ref-type="bibr">2014</xref>).</p><p>Prior to recent years, animal studies relating to the effects of oxytocin have mainly focused on single dose administration, and in an adult population. On review of current animal data (Table <xref ref-type="table" rid="T1">1</xref>), there were four studies identified investigating administration of oxytocin via intraperitoneal injection, and three studies using intranasal oxytocin in young.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p><bold>Acute and long-term effects of oxytocin administration in young animals</bold>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"><bold>Study</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Study Type</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Sample</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Gender</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Focus</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Dose of OXT and route of administration</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Duration of treatment</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Behavioral Observations</bold></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Bales and Perkeybile, <xref rid="B4" ref-type="bibr">2012</xref></td><td valign="top" align="left" rowspan="1" colspan="1">Prairie voles</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>N</italic> = 89;</td><td valign="top" align="left" rowspan="1" colspan="1">Male and female</td><td valign="top" align="left" rowspan="1" colspan="1">Acute and long-term</td><td valign="top" align="left" rowspan="1" colspan="1">IN:</td><td valign="top" align="left" rowspan="1" colspan="1">21 days</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0201c;Prosocial effects&#x0201d; identified following single dose administration. Impaired formation of pair-bond in male voles in dose-dependent curve</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Blind study: OXT or saline;</td><td valign="top" align="left" rowspan="1" colspan="1">EXPOSED PND 21&#x02013;42 days old (adolescence)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Low = 0.08 IU/kg</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Med = 0.8 IU/kg</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">High = 8.0 IU/kg</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Bales et al., <xref rid="B7" ref-type="bibr">2007</xref></td><td valign="top" align="left" rowspan="1" colspan="1">Prairie voles; saline or one of four dosages of oxytocin</td><td valign="top" align="left" rowspan="1" colspan="1">Neonates (PND1); <italic>N</italic> = 8&#x02013;12 per group</td><td valign="top" align="left" rowspan="1" colspan="1">Female</td><td valign="top" align="left" rowspan="1" colspan="1">Long-term</td><td valign="top" align="left" rowspan="1" colspan="1">2, 4 or 8 mg/kg injection</td><td valign="top" align="left" rowspan="1" colspan="1">1 day</td><td valign="top" align="left" rowspan="1" colspan="1">Effects differed per dose, but not linear. Both increase and decrease the propensity to display behaviors such as pair-bonding</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Bales et al., <xref rid="B6" ref-type="bibr">2004</xref></td><td valign="top" align="left" rowspan="1" colspan="1">Prairie voles; saline, oxytocin or antagonist</td><td valign="top" align="left" rowspan="1" colspan="1">Neonates (PND1)</td><td valign="top" align="left" rowspan="1" colspan="1">Male and female</td><td valign="top" align="left" rowspan="1" colspan="1">Long-term</td><td valign="top" align="left" rowspan="1" colspan="1">IP</td><td valign="top" align="left" rowspan="1" colspan="1">1 day</td><td valign="top" align="left" rowspan="1" colspan="1">Different effects on social and anxiety behavior in the sexes</td></tr><tr><td valign="top" align="left" rowspan="2" colspan="1">Rault et al., <xref rid="B56" ref-type="bibr">2013</xref></td><td valign="top" align="left" rowspan="1" colspan="1">Pigs</td><td valign="top" align="left" rowspan="2" colspan="1"><italic>N</italic> = 24; EXPOSED PND 1&#x02013;3; (neonates)</td><td valign="top" align="left" rowspan="2" colspan="1">Male and female</td><td valign="top" align="left" rowspan="2" colspan="1">Acute and long-term</td><td valign="top" align="left" rowspan="2" colspan="1">IN 24 IU</td><td valign="top" align="left" rowspan="2" colspan="1">3 days (daily dosing at 1,2,3 days of age)</td><td valign="top" align="left" rowspan="2" colspan="1">Neonatally OT-administered pigs received increased aggressive interactions and showed aggressive behaviors, increased locomotion, less social contact and raised cortisol levels at 17 days and 8 weeks. Decreased responsiveness on dexamethasone suppression test at 11 weeks</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">OXT or saline; acute and long-term</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Simpson et al., <xref rid="B59" ref-type="bibr">2014</xref></td><td valign="top" align="left" rowspan="1" colspan="1">Newborn macaques</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>N</italic> = 28;</td><td valign="top" align="left" rowspan="1" colspan="1">Male and female</td><td valign="top" align="left" rowspan="1" colspan="1">Long-term</td><td valign="top" align="left" rowspan="1" colspan="1">IN dose unquantified</td><td valign="top" align="left" rowspan="1" colspan="1">7 days</td><td valign="top" align="left" rowspan="1" colspan="1">Increased affiliation, communication gestures</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Blind study: OXT or saline</td><td valign="top" align="left" rowspan="1" colspan="1">Newborn macaques</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Long-term effects</td><td valign="top" align="left" rowspan="1" colspan="1">EXPOSED PND 7-14</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Bowen et al., <xref rid="B11" ref-type="bibr">2011</xref></td><td valign="top" align="left" rowspan="1" colspan="1">Wistar Rats</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>N</italic> = 48; PND 33&#x02013;42 (early adolescence)</td><td valign="top" align="left" rowspan="1" colspan="1">Male</td><td valign="top" align="left" rowspan="1" colspan="1">Long-term</td><td valign="top" align="left" rowspan="1" colspan="1">1 mg/kg IP</td><td valign="top" align="left" rowspan="1" colspan="1">PND 33&#x02013;42</td><td valign="top" align="left" rowspan="1" colspan="1">Less anxiety, more sociability and reduced motivation to consume alcohol. Changes to OX system</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Suraev et al., <xref rid="B60" ref-type="bibr">2014</xref></td><td valign="top" align="left" rowspan="1" colspan="1">Long-Evans Rats, Oxytocin or selective</td><td valign="top" align="left" rowspan="1" colspan="1">PND 28&#x02013;55; (Adolescence)</td><td valign="top" align="left" rowspan="1" colspan="1">Male</td><td valign="top" align="left" rowspan="1" colspan="1">Acute and long-term effects</td><td valign="top" align="left" rowspan="1" colspan="1">0.5&#x02013;1 mg/kg, IP; intermittent regime of OT exposure (10 doses in total)</td><td valign="top" align="left" rowspan="1" colspan="1">During entire adolescence PND 28&#x02013;55</td><td valign="top" align="left" rowspan="1" colspan="1">Acute decrease in social play and possible sedation;</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">OXTR agonist</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Long-term: increase social interaction;</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Increased plasma oxytocin.</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Selective oxytocin agonist could not fully mimic effects, implicating V1aR in some effects</td></tr></tbody></table><table-wrap-foot><p><italic>PND, postnatal day; IN, Intranasal; IP, Intraperitoneal</italic>.</p></table-wrap-foot></table-wrap><p>Studies focusing on intraperitoneal oxytocin injection reinforced inconsistent findings displayed in earlier data according to dose and measured outcome variable, and further highlighted that in the short-term, oxytocin administration may lead to a decrease in positive social behaviors (Suraev et al., <xref rid="B60" ref-type="bibr">2014</xref>), whilst in the long term contribute to heightened social interaction and diminished display of anxiety (Bowen et al., <xref rid="B11" ref-type="bibr">2011</xref>) (see Table <xref ref-type="table" rid="T1">1</xref>).</p><p>All three animal studies investigating intranasal oxytocin involved repeated dosing. Firstly, Bales et al., found repeated dosing during adolescence had long-term effects on partner preference in prairie voles (Bales et al., <xref rid="B5" ref-type="bibr">2013</xref>). Secondly, Rault et al., found that neonatal pigs displayed increased aggressive behaviors and locomotion, and diminished social contact following daily intranasal oxytocin administration in days 1&#x02013;3 of life. In addition, there was decreased responsiveness on dexamethasone suppression test at 11 weeks, suggesting repeated intranasal oxytocin administration in early life can cause chronic dysregulation of the hypothalamic-pituitary axis (Rault et al., <xref rid="B56" ref-type="bibr">2013</xref>). Most recently, Simpson et al., found that in newborn rhesus monkeys, administration of daily intranasal oxytocin increased an infant's affiliative communication gestures and decreased salivary cortisol levels (Simpson et al., <xref rid="B59" ref-type="bibr">2014</xref>). In a similar trend identified in the administration of oxytocin via intraperitoneal injection in young animals, the use of intranasal oxytocin produced largely variable results, which appeared to be dose-dependent. Whilst prosocial effects and a decrease in salivary cortisol levels were some of the positive outcomes observed, authors also commented on intranasal oxytocin administration in young animals having the potential to increase aggressive behaviors, impair pair-bond formation, and lead to disruption of the HPA-axis.</p><p>A thorough review of current literature found that there were only six human studies (Table <xref ref-type="table" rid="T2">2</xref>) focusing on the use of intranasal oxytocin in a child or adolescent population. Of these studies, five occurred in populations with a diagnosis of ASDs (Guastella et al., <xref rid="B29" ref-type="bibr">2010</xref>; Gordon et al., <xref rid="B28" ref-type="bibr">2013</xref>; Tachibana et al., <xref rid="B61" ref-type="bibr">2013</xref>; Dadds et al., <xref rid="B20" ref-type="bibr">2014</xref>; Guastella et al., <xref rid="B30" ref-type="bibr">2014</xref>), and one in a population with Fragile X Syndrome (Hall et al., <xref rid="B33" ref-type="bibr">2012</xref>). Of these six studies, Guastella et al.'s (<xref rid="B30" ref-type="bibr">2014</xref>) RCT investigating the effects of a course of intranasal oxytocin on social behaviors in youths with ASDs, and Tachibana et al., were the only groups to investigate chronic administration of intranasal oxytocin over 2, and 6 month periods, respectively, although there was notably a small sample size in the later study. Moreover, only three of the relevant studies found on review included children under the age of 12 (Gordon et al.; Dadds et al.; Tachibana et al.), with a clear lack of data pertaining to the effect of intranasal oxytocin administration in the neonatal and early childhood/pre-pubertal stages of development, a time during which the oxytocin system displays its highest degree of neuroplasticity. From a broader perspective, review of the current literature of intranasal oxytocin use in child and adolescent populations highlighted significant limitations to inferring clinically significant results, and recognizing consistent patterns of effect between studies, including: small sample sizes, limited data on chronic use compared to single-dose administration, and a predilection toward male subjects.</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p><bold>Intranasal oxytocin administration in children and adolescents (0&#x02013;18 year old)</bold>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"><bold>Study</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Study type</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Sample</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Gender</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Primary targeted disorder</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Dose of OXT (IU)</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Duration of treatment</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Side effects</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Clinical outcome</bold></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="3" colspan="1">Dadds et al., <xref rid="B20" ref-type="bibr">2014</xref></td><td valign="top" align="left" rowspan="3" colspan="1">Double-blind RCT: IN OXT vs. placebo</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>n</italic> = 38;</td><td valign="top" align="left" rowspan="3" colspan="1">Male</td><td valign="top" align="left" rowspan="3" colspan="1">Autism Spectrum disorders</td><td valign="top" align="left" rowspan="3" colspan="1">12 or 24 dose calculated on weight</td><td valign="top" align="left" rowspan="3" colspan="1">Daily dosing over 4 consecutive days</td><td valign="top" align="left" rowspan="3" colspan="1">No significant side-effects reported</td><td valign="top" align="left" rowspan="3" colspan="1">No significant improvement in emotional recognition, social interaction skills, or general behavioral adjustment on pre vs. post dose assessments</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Mean age: 11.2 &#x000b1; 2.6 years</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">(range:7&#x02013;16 years)</td></tr><tr><td valign="top" align="left" rowspan="2" colspan="1">Guastella et al., <xref rid="B30" ref-type="bibr">2014</xref></td><td valign="top" align="left" rowspan="1" colspan="1">Double-blind, placebo-controlled trial</td><td valign="top" align="left" rowspan="2" colspan="1"><italic>n</italic> = 50; Age range 12&#x02013;18 years</td><td valign="top" align="left" rowspan="2" colspan="1">Male</td><td valign="top" align="left" rowspan="2" colspan="1">Autism Spectrum Disorders</td><td valign="top" align="left" rowspan="2" colspan="1">18 or 24 IU twice daily dosing</td><td valign="top" align="left" rowspan="1" colspan="1">Twice daily dosing for 8 weeks</td><td valign="top" align="left" rowspan="2" colspan="1">No side effects reported</td><td valign="top" align="left" rowspan="2" colspan="1">No overall significant improvement/ clinical efficacy identified in subjects receiving course of intranasal oxytocin</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">IN OXT vs. placebo</td><td valign="top" align="left" rowspan="1" colspan="1">Follow-up at baseline, a 4,8,12 weeks post treatment</td></tr><tr><td valign="top" align="left" rowspan="3" colspan="1">Guastella et al., <xref rid="B29" ref-type="bibr">2010</xref></td><td valign="top" align="left" rowspan="3" colspan="1">Crossover design: IN OXT vs. placebo</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>n</italic> = 16;</td><td valign="top" align="left" rowspan="3" colspan="1">Male</td><td valign="top" align="left" rowspan="3" colspan="1">Autism Spectrum Disorders</td><td valign="top" align="left" rowspan="3" colspan="1">Single dose 18&#x02013;24 IU depending on age</td><td valign="top" align="left" rowspan="3" colspan="1">Intervals between sessions unspecified</td><td valign="top" align="left" rowspan="3" colspan="1">No significant side-effects</td><td valign="top" align="left" rowspan="3" colspan="1">OXT improved performance on Reading the Mind in the Eyes test (RMET) in 60% subjects</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Mean age: 14.8 &#x000b1; 2.4</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">(range:12&#x02013;19)</td></tr><tr><td valign="top" align="left" rowspan="2" colspan="1">Tachibana et al., <xref rid="B61" ref-type="bibr">2013</xref></td><td valign="top" align="left" rowspan="1" colspan="1">Single-armed open label study</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>n</italic> = 8;</td><td valign="top" align="left" rowspan="2" colspan="1">Male</td><td valign="top" align="left" rowspan="2" colspan="1">Autism Spectrum Disorders</td><td valign="top" align="left" rowspan="2" colspan="1">Incremental doses every 2 months from 8 IU, 16 IU, 24 IU with 1&#x02013;2 week placebo period prior to each dose increase</td><td valign="top" align="left" rowspan="2" colspan="1">6 months active treatment, up to 6 weeks total placebo prior to each dose increase</td><td valign="top" align="left" rowspan="2" colspan="1">No side effects reported</td><td valign="top" align="left" rowspan="2" colspan="1">6 of 8 subjects displayed improved scores on the ADOS-G. Caregivers report improvement in reciprocal communication</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">IN OXT vs. placebo</td><td valign="top" align="left" rowspan="1" colspan="1">Age range 10&#x02013;14 years</td></tr><tr><td valign="top" align="left" rowspan="3" colspan="1">Hall et al., <xref rid="B33" ref-type="bibr">2012</xref></td><td valign="top" align="left" rowspan="3" colspan="1">Crossover design: IN OXT vs. placebo</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>n</italic> = 8;</td><td valign="top" align="left" rowspan="3" colspan="1">Male</td><td valign="top" align="left" rowspan="3" colspan="1">Fragile X Syndrome</td><td valign="top" align="left" rowspan="3" colspan="1">24&#x02013;48 IU</td><td valign="top" align="left" rowspan="3" colspan="1">OXT vs. placebo challenges separated by 1 week</td><td valign="top" align="left" rowspan="3" colspan="1">No side effects or adverse events reported</td><td valign="top" align="left" rowspan="3" colspan="1">Improved eye gaze frequency in response to 24 IU IN OXT. Decrease in salivary cortisol levels in response to 48 IU OXT</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Mean age:21.3 &#x000b1; 5.1 years</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">(range: 13&#x02013;28)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Gordon et al., <xref rid="B28" ref-type="bibr">2013</xref></td><td valign="top" align="left" rowspan="1" colspan="1">Randomized, Double-blind, crossover functional MRI study</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>n</italic> = 21;</td><td valign="top" align="left" rowspan="1" colspan="1">Female</td><td valign="top" align="left" rowspan="1" colspan="1">High-functioning</td><td valign="top" align="left" rowspan="1" colspan="1">7&#x02013;11 years</td><td valign="top" align="left" rowspan="1" colspan="1">Single dose</td><td valign="top" align="left" rowspan="1" colspan="1">No significant side-effects reported</td><td valign="top" align="left" rowspan="1" colspan="1">Increased activity in &#x0201c;social regions&#x0201d;/neural networks on fMRI imaging using the RMET test</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">IN OXT vs. placebo</td><td valign="top" align="left" rowspan="1" colspan="1">Age range 8&#x02013;16.5 years</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>n</italic> = 3</td><td valign="top" align="left" rowspan="1" colspan="1">Autism Spectrum Disorders</td><td valign="top" align="left" rowspan="1" colspan="1">dose = 12 IU</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">12&#x02013;15 years</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><italic>n</italic> = 18</td><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">dose = 18 or 24 IU</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">16&#x02013;19 years</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">dose = 24 IU</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><p><italic>IU, International Unit</italic>.</p></table-wrap-foot></table-wrap><p>Studies identifying beneficial clinical outcomes to intranasal oxytocin administration were (1) Gordon et al., who found improved performance in detecting socially salient information on a well-validated fMRI emotion judgment task (&#x0201c;Reading the Mind in the Eyes Test&#x0201d;) following intranasal oxytocin, in addition to identifying that oxytocin enhances activity in social brain regions (see Table <xref ref-type="table" rid="T2">2</xref>) (Gordon et al., <xref rid="B28" ref-type="bibr">2013</xref>), (2) Guastella et al., in their 2010 crossover study who displayed improved performance on the RMET in 60% of subjects following intranasal oxytocin administration (Guastella et al., <xref rid="B29" ref-type="bibr">2010</xref>), (3) Hall et al., who reported improved frequency of eye gaze at a specific dose oxytocin, in addition to decreased salivary cortisol levels in subjects receiving a specific dose (Hall et al., <xref rid="B33" ref-type="bibr">2012</xref>) and (4) Tachibana et al.,'s study revealing six of a total 8 male youths with a primary diagnosis of ASD displayed improved performance on communication and social interaction domains of the Autism Diagnostic Observation Schedule-Generic (ADOS-G) following incremental dose increases of intranasal oxytocin over a 6 month period (see Table <xref ref-type="table" rid="T2">2</xref>).</p><p>The most recent studies by Dadds et al., and Guastella et al., do not report identified significant clinical benefit following the administration of oxytocin.</p><p>Despite an evolving scope of current animal and human research data relating to the use of intranasal oxytocin in adults, studies relevant to young animals, and the pediatric population remain limited to date. Factors contributing to this may be related the uncertainty of risks of single, or multiple oxytocin dose administrations on the developing brain, in addition to an absence of clear methods to measure outcome (Miller et al., <xref rid="B47" ref-type="bibr">2013</xref>). Review highlighted no significant reporting of side effects or adverse events in the studied populations, with multiple studies referring to intranasal oxytocin being well-tolerated.</p></sec><sec><title>The expected benefits and risks of intranasal oxytocin in pediatric populations</title><p>In assessing expected risks and benefits of oxytocin administration in the pediatric population, it will be important to first consider basic principles of neuroadaptation, including the development of tolerance, changes in receptor numbers, and receptor sensitivity, related to repeated exposure of any drug.</p><p>Based on current research data in adult animal and human populations, and the promising findings noted in behavioral modulation (Miller, <xref rid="B46" ref-type="bibr">2013</xref>; Love, <xref rid="B43" ref-type="bibr">2014</xref>), translational studies to the pediatric population could too hold promise. There is a potentially broad scope of application for the use of intranasal oxytocin based on mental health disorders or presentations that are characterized by a decreased responsiveness to social cues, emotional dysregulation and aggression. It would also be of interest to determine if the positive findings in the field of oxytocin and substance addiction (Bowen et al., <xref rid="B11" ref-type="bibr">2011</xref>; Buisman-Pijlman et al., <xref rid="B14" ref-type="bibr">2014a</xref>) were reproducible in younger populations.</p><p>As outlined by Miller et al. (<xref rid="B47" ref-type="bibr">2013</xref>) in their study reviewing the role of gender in regards to symptomatology in ASDs, there are variations in oxytocin and vasopressin identified between sexes (Miller et al., <xref rid="B47" ref-type="bibr">2013</xref>). Broader application of this principle and an understanding of baseline variations in endogenous oxytocin levels between sexes will likely be important in future research involving administration of intranasal oxytocin to both young males and females for various mental health disorders.</p><p>In recent reviews, authors have commented on &#x0201c;cascading effects&#x0201d; of intranasal oxytocin (Veening and Olivier, <xref rid="B63" ref-type="bibr">2013</xref>) whereby administration of intranasal oxytocin also stimulates release of peripherally acting oxytocin (Veening and Olivier, <xref rid="B63" ref-type="bibr">2013</xref>). One rat study did report increased basal levels of oxytocin after long-term administration during adolescence (Suraev et al., <xref rid="B60" ref-type="bibr">2014</xref>); the opposite could be possible as well-depending on the age of exposure. Potentially detrimental effects of inadvertently raising systemic levels of oxytocin remain unclear both in the adult and pediatric population, and would require further investigation from a safety perspective.</p></sec><sec><title>Risks of oxytocin in children with severe psychopathology and early life trauma</title><p>As outlined, the oxytocin neuropeptide system in humans remains in an evolutionary state with ongoing plasticity throughout infancy, early childhood, and during adolescence (Buisman-Pijlman et al., <xref rid="B15" ref-type="bibr">2014b</xref>).</p><p>Those impacted by significant early life trauma are more likely to display a heightened degree of emotional dysregulation (Antoniadis et al., <xref rid="B2" ref-type="bibr">2012</xref>). It is well-recognized in psychiatric practice that emotional dysregulation, impulsivity, and relationship instability are clinical features of psychopathology in Borderline Personality Disorder that are likely to be in an evolutionary state during adolescence (Barnow et al., <xref rid="B8" ref-type="bibr">2012</xref>). The role of oxytocin in modulating the relational capacities in children and adolescents has been considered extensively in the literature, particular in relation to attachment disorders, anxiety and autism-spectrum disorders (Meyer-Lindenberg et al., <xref rid="B45" ref-type="bibr">2011</xref>; Frijling et al., <xref rid="B27" ref-type="bibr">2014</xref>).</p><p>The effect of intranasal oxytocin on these subjects might be difficult to predict. In addition, there will need to be a heightened awareness of the interconnectivity of for example the dopaminergic, serotonergic, and noradrenergic systems (Tops et al., <xref rid="B62" ref-type="bibr">2014</xref>), and potential effects this poses, with oxytocin administration. In a clinical subgroup already plagued by attachment and relational difficulties, further concern is warranted given the risk of oxytocin administration leading to long-lasting behavioral and social, and neuroendocrine consequences (Miller, <xref rid="B46" ref-type="bibr">2013</xref>).</p><p>The current research in fact suggests that oxytocin administration (intranasally) in the clinical settings for autism, social anxiety disorder, post-natal depression, obsessive-compulsive disorder, schizophrenia, borderline personality disorder, and post-traumatic stress disorder, yield minimal improvement in emotion recognition and interpersonal trust. In the context of developmental trauma, positive effects (behaviorally or neurobiologically) were in fact lowered or absent (Bakermans-Kranenburg and van I Jzendoorn, <xref rid="B3" ref-type="bibr">2013</xref>). It may be more feasible to identify improvements in disorders that have a homogenous etiology and little comorbidity.</p></sec><sec sec-type="discussion" id="s2"><title>Discussion</title><p>An evolving wealth of animal and human data relating to the neuro-modulatory role of the endogenous oxytocin system, its interactions with other neural pathways, and its implications on behaviors from a neuroscience perspective is expanding at an exponential rate (Tops et al., <xref rid="B62" ref-type="bibr">2014</xref>). There is evidence highlighting (1) the importance of oxytocin in attachment (Love, <xref rid="B43" ref-type="bibr">2014</xref>) and (2)the factors that may lead to individual variations in the endogenous oxytocin system including early life trauma and environmental factors (Buisman-Pijlman et al., <xref rid="B15" ref-type="bibr">2014b</xref>). This highlights further potential research questions based around whether attachment difficulties may be in part modifiable not only through psycho-education and implementation of behavioral strategies, but through implementation of pharmacotherapies for high-risk populations.</p><p>Furthermore the benefits of intranasal oxytocin administration in the adult population are now also becoming clearer, and the potential clinical applications more far-reaching. Researchers are now investigating the potential use of intranasal oxytocin in the treatment of depression as an adjunct to selective serotonin reuptake inhibitors (Emiliano et al., <xref rid="B24" ref-type="bibr">2007</xref>), anxiety (Guastella et al., <xref rid="B31" ref-type="bibr">2009</xref>), and more recently, anorexia nervosa (Kim et al., <xref rid="B39" ref-type="bibr">2014</xref>) with promising preliminary results findings. This data would be of high clinical relevance if translated to trials targeting the adolescent population in which affective, anxiety and eating disorders are also prevalent. There are limited animal and human studies reflecting consistent results to date in pediatric populations, with the vast majority focusing on the use of intranasal oxytocin in modifying behaviors related to ASDs. There are fundamental considerations relating to neuroplasticity, neuro-adaptation and the impact of significant psychopathology that remain inadequately explored, and will likely inform further discussions around the safety of intranasal oxytocin as a therapeutic intervention. Based on our knowledge of the context-dependent nature (Guastella and Macleod, <xref rid="B32" ref-type="bibr">2012</xref>), and plasticity of oxytocin system (Buisman-Pijlman et al., <xref rid="B15" ref-type="bibr">2014b</xref>), animal and human studies are challenging to translate to pediatric populations. In addition, further questions relating to sensitive and specific methods of measuring outcomes in potential trials need consideration. Addressing these issues could lead to a broader wealth of research relating to oxytocin in pediatric populations, findings of which would likely continue to inform the way in which therapeutic interventions in the child and adolescent population are considered in the future.</p><sec><title>Conflict of interest statement</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></sec></body><back><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ansseau</surname><given-names>M.</given-names></name><name><surname>Legros</surname><given-names>J. J.</given-names></name><name><surname>Mormont</surname><given-names>C.</given-names></name><name><surname>Cerfontaine</surname><given-names>J. L.</given-names></name><name><surname>Papart</surname><given-names>P.</given-names></name><name><surname>Geenen</surname><given-names>V.</given-names></name><etal/></person-group> (<year>1987</year>). <article-title>Intranasal oxytocin in obsessive-compulsive disorder</article-title>. <source>Psychoneuroendocrinology</source><volume>12</volume>, <fpage>231</fpage>&#x02013;<lpage>236</lpage>. <pub-id pub-id-type="doi">10.1016/0306-4530(87)90009-6</pub-id><?supplied-pmid 3615752?><pub-id pub-id-type="pmid">3615752</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antoniadis</surname><given-names>D.</given-names></name><name><surname>Samakouri</surname><given-names>M.</given-names></name><name><surname>Livaditis</surname><given-names>M.</given-names></name></person-group> (<year>2012</year>). <article-title>The association of bipolar spectrum disorders and borderline personality disorder</article-title>. <source>Psychiatr. Q</source>. <volume>83</volume>, <fpage>449</fpage>&#x02013;<lpage>465</lpage>. <pub-id pub-id-type="doi">10.1007/s11126-012-9214-6</pub-id><?supplied-pmid 22392448?><pub-id pub-id-type="pmid">22392448</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bakermans-Kranenburg</surname><given-names>M. J.</given-names></name><name><surname>van I Jzendoorn</surname><given-names>M. H.</given-names></name></person-group> (<year>2013</year>). <article-title>Sniffing around oxytocin: review and meta-analyses of trials in healthy and clinical groups with implications for pharmacotherapy</article-title>. <source>Transl. Psychiatry</source>
<volume>3</volume>, <fpage>e258</fpage>
<pub-id pub-id-type="doi">10.1038/tp.2013.34</pub-id><?supplied-pmid 23695233?><pub-id pub-id-type="pmid">23695233</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bales</surname><given-names>K. L.</given-names></name><name><surname>Perkeybile</surname><given-names>A. M.</given-names></name></person-group> (<year>2012</year>). <article-title>Developmental experiences and the oxytocin receptor system</article-title>. <source>Horm. Behav</source>. <volume>61</volume>, <fpage>313</fpage>&#x02013;<lpage>319</lpage>. <pub-id pub-id-type="doi">10.1016/j.yhbeh.2011.12.013</pub-id><?supplied-pmid 22245313?><pub-id pub-id-type="pmid">22245313</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bales</surname><given-names>K. L.</given-names></name><name><surname>Perkeybile</surname><given-names>A. M.</given-names></name><name><surname>Conley</surname><given-names>O. G.</given-names></name><name><surname>Lee</surname><given-names>M. H.</given-names></name><name><surname>Guoynes</surname><given-names>C. D.</given-names></name><name><surname>Downing</surname><given-names>G. M.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Chronic intranasal oxytocin causes long-term impairments in partner preference formation in male prairie voles</article-title>. <source>Biol. Psychiatry</source>
<volume>74</volume>, <fpage>180</fpage>&#x02013;<lpage>188</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2012.08.025</pub-id><?supplied-pmid 23079235?><pub-id pub-id-type="pmid">23079235</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bales</surname><given-names>K. L.</given-names></name><name><surname>Pfeifer</surname><given-names>L. A.</given-names></name><name><surname>Carter</surname><given-names>C. S.</given-names></name></person-group> (<year>2004</year>). <article-title>Sex differences and developmental effects of manipulations of oxytocin on alloparenting and anxiety in prairie voles</article-title>. <source>Dev. Psychobiol</source>. <volume>44</volume>, <fpage>123</fpage>&#x02013;<lpage>131</lpage>. <pub-id pub-id-type="doi">10.1002/dev.10165</pub-id><?supplied-pmid 14994263?><pub-id pub-id-type="pmid">14994263</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bales</surname><given-names>K. L.</given-names></name><name><surname>Van Westerhuyzen</surname><given-names>J. A.</given-names></name><name><surname>Lewis-Reese</surname><given-names>A. D.</given-names></name><name><surname>Grotte</surname><given-names>N. D.</given-names></name><name><surname>Lanter</surname><given-names>J. A.</given-names></name><name><surname>Carter</surname><given-names>C. S.</given-names></name></person-group> (<year>2007</year>). <article-title>Oxytocin has dose-dependent developmental effects on pair-bonding and alloparental care in female prairie voles</article-title>. <source>Horm. Behav</source>. <volume>52</volume>, <fpage>274</fpage>&#x02013;<lpage>279</lpage>. <pub-id pub-id-type="doi">10.1016/j.yhbeh.2007.05.004</pub-id><?supplied-pmid 17553502?><pub-id pub-id-type="pmid">17553502</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barnow</surname><given-names>S.</given-names></name><name><surname>Limberg</surname><given-names>A.</given-names></name><name><surname>Stopsack</surname><given-names>M.</given-names></name><name><surname>Spitzer</surname><given-names>C.</given-names></name><name><surname>Grabe</surname><given-names>H. J.</given-names></name><name><surname>Freyberger</surname><given-names>H. J.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Dissociation and emotion regulation in borderline personality disorder</article-title>. <source>Psychol. Med</source>. <volume>42</volume>, <fpage>783</fpage>&#x02013;<lpage>794</lpage>. <pub-id pub-id-type="doi">10.1017/S0033291711001917</pub-id><?supplied-pmid 22067328?><pub-id pub-id-type="pmid">22067328</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baumgartner</surname><given-names>T.</given-names></name><name><surname>Heinrichs</surname><given-names>M.</given-names></name><name><surname>Vonlanthen</surname><given-names>A.</given-names></name><name><surname>Fischbacher</surname><given-names>U.</given-names></name><name><surname>Fehr</surname><given-names>E.</given-names></name></person-group> (<year>2008</year>). <article-title>Oxytocin shapes the neural circuitry of trust and trust adaptation in humans</article-title>. <source>Neuron</source>
<volume>58</volume>, <fpage>639</fpage>&#x02013;<lpage>650</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2008.04.009</pub-id><?supplied-pmid 18498743?><pub-id pub-id-type="pmid">18498743</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beetz</surname><given-names>A.</given-names></name><name><surname>Uvnas-Moberg</surname><given-names>K.</given-names></name><name><surname>Julius</surname><given-names>H.</given-names></name><name><surname>Kotrschal</surname><given-names>K.</given-names></name></person-group> (<year>2012</year>). <article-title>Psychosocial and psychophysiological effects of human-animal interactions: the possible role of oxytocin</article-title>. <source>Front. Psychol</source>. <volume>3</volume>:<issue>234</issue>
<pub-id pub-id-type="doi">10.3389/fpsyg.2012.00234</pub-id><?supplied-pmid 22866043?><pub-id pub-id-type="pmid">22866043</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bowen</surname><given-names>M. T.</given-names></name><name><surname>Carson</surname><given-names>D. S.</given-names></name><name><surname>Spiro</surname><given-names>A.</given-names></name><name><surname>Arnold</surname><given-names>J. C.</given-names></name><name><surname>McGregor</surname><given-names>I. S.</given-names></name></person-group> (<year>2011</year>). <article-title>Adolescent oxytocin exposure causes persistent reductions in anxiety and alcohol consumption and enhances sociability in rats</article-title>. <source>PLoS ONE</source>
<volume>6</volume>:<fpage>e27237</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0027237</pub-id><?supplied-pmid 22110618?><pub-id pub-id-type="pmid">22110618</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bowlby</surname><given-names>J.</given-names></name></person-group> (<year>1960</year>). <article-title>Separation anxiety</article-title>. <source>Int. J. Psychoanal</source>. <volume>41</volume>, <fpage>89</fpage>&#x02013;<lpage>113</lpage>. <?supplied-pmid 13803480?><pub-id pub-id-type="pmid">13803480</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Broadbear</surname><given-names>J. H.</given-names></name><name><surname>Kabel</surname><given-names>D.</given-names></name><name><surname>Tracy</surname><given-names>L.</given-names></name><name><surname>Mak</surname><given-names>P.</given-names></name></person-group> (<year>2014</year>). <article-title>Oxytocinergic regulation of endogenous as well as drug-induced mood</article-title>. <source>Pharmacol. Biochem. Behav</source>. <volume>119</volume>, <fpage>61</fpage>&#x02013;<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1016/j.pbb.2013.07.002</pub-id><?supplied-pmid 23872370?><pub-id pub-id-type="pmid">23872370</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buisman-Pijlman</surname><given-names>F. T.</given-names></name><name><surname>Broadbear</surname><given-names>J. H.</given-names></name><name><surname>Sarnyai</surname><given-names>Z.</given-names></name></person-group> (<year>2014a</year>). <article-title>Guest editorial. The role of oxytocin in positive affect and drug-related reward</article-title>. <source>Pharmacol. Biochem. Behav</source>. <volume>119</volume>, <fpage>1</fpage>&#x02013;<lpage>2</lpage>. <pub-id pub-id-type="doi">10.1016/j.pbb.2013.11.023</pub-id><?supplied-pmid 24287105?><pub-id pub-id-type="pmid">24287105</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buisman-Pijlman</surname><given-names>F. T.</given-names></name><name><surname>Sumracki</surname><given-names>N. M.</given-names></name><name><surname>Gordon</surname><given-names>J. J.</given-names></name><name><surname>Hull</surname><given-names>P. R.</given-names></name><name><surname>Carter</surname><given-names>C. S.</given-names></name><name><surname>Tops</surname><given-names>M.</given-names></name></person-group> (<year>2014b</year>). <article-title>Individual differences underlying susceptibility to addiction: role for the endogenous oxytocin system</article-title>. <source>Pharmacol. Biochem. Behav</source>. <volume>119</volume>, <fpage>22</fpage>&#x02013;<lpage>38</lpage>. <pub-id pub-id-type="doi">10.1016/j.pbb.2013.09.005</pub-id><?supplied-pmid 24056025?><pub-id pub-id-type="pmid">24056025</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname><given-names>D. B.</given-names></name><name><surname>Datta</surname><given-names>D.</given-names></name><name><surname>Jones</surname><given-names>S. T.</given-names></name><name><surname>Batey Lee</surname><given-names>E.</given-names></name><name><surname>Sutcliffe</surname><given-names>J. S.</given-names></name><name><surname>Hammock</surname><given-names>E. A.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Association of oxytocin receptor (OXTR) gene variants with multiple phenotype domains of autism spectrum disorder</article-title>. <source>J. Neurodev. Disord</source>. <volume>3</volume>, <fpage>101</fpage>&#x02013;<lpage>112</lpage>. <pub-id pub-id-type="doi">10.1007/s11689-010-9071-2</pub-id><?supplied-pmid 21484202?><pub-id pub-id-type="pmid">21484202</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Churchland</surname><given-names>P. S.</given-names></name><name><surname>Winkielman</surname><given-names>P.</given-names></name></person-group> (<year>2012</year>). <article-title>Modulating social behavior with oxytocin: how does it work? What does it mean?</article-title>
<source>Horm. Behav</source>. <volume>61</volume>, <fpage>392</fpage>&#x02013;<lpage>399</lpage>. <pub-id pub-id-type="doi">10.1016/j.yhbeh.2011.12.003</pub-id><?supplied-pmid 22197271?><pub-id pub-id-type="pmid">22197271</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>J.</given-names></name><name><surname>Danezis</surname><given-names>J.</given-names></name><name><surname>Burnhill</surname><given-names>M. S.</given-names></name></person-group> (<year>1962</year>). <article-title>Response of the gravid uterus at term to intranasal oxytocin as determined by intra-amniotic fluid pressure recordings</article-title>. <source>Am. J. Obstet. Gynecol</source>. <volume>83</volume>, <fpage>774</fpage>&#x02013;<lpage>777</lpage>. <?supplied-pmid 13880264?><pub-id pub-id-type="pmid">13880264</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dadds</surname><given-names>M. R.</given-names></name><name><surname>Macdonald</surname><given-names>E.</given-names></name><name><surname>Cauchi</surname><given-names>A.</given-names></name><name><surname>Williams</surname><given-names>K.</given-names></name><name><surname>Levy</surname><given-names>F.</given-names></name><name><surname>Brennan</surname><given-names>J.</given-names></name></person-group> (<year>2014</year>). <article-title>Nasal oxytocin for social deficits in childhood autism: a randomized controlled trial</article-title>. <source>J. Autism Dev. Disord</source>. <volume>44</volume>, <fpage>521</fpage>&#x02013;<lpage>531</lpage>. <pub-id pub-id-type="doi">10.1007/s10803-013-1899-3</pub-id><?supplied-pmid 23888359?><pub-id pub-id-type="pmid">23888359</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Den Boer</surname><given-names>J. A.</given-names></name><name><surname>Westenberg</surname><given-names>H. G.</given-names></name></person-group> (<year>1992</year>). <article-title>Oxytocin in obsessive compulsive disorder</article-title>. <source>Peptides</source>
<volume>13</volume>, <fpage>1083</fpage>&#x02013;<lpage>1085</lpage>. <pub-id pub-id-type="doi">10.1016/0196-9781(92)90010-Z</pub-id><?supplied-pmid 1494489?><pub-id pub-id-type="pmid">1494489</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dolen</surname><given-names>G.</given-names></name><name><surname>Darvishzadeh</surname><given-names>A.</given-names></name><name><surname>Huang</surname><given-names>K. W.</given-names></name><name><surname>Malenka</surname><given-names>R. C.</given-names></name></person-group> (<year>2013</year>). <article-title>Social reward requires coordinated activity of nucleus accumbens oxytocin and serotonin</article-title>. <source>Nature</source>
<volume>501</volume>, <fpage>179</fpage>&#x02013;<lpage>184</lpage>. <pub-id pub-id-type="doi">10.1038/nature12518</pub-id><?supplied-pmid 24025838?><pub-id pub-id-type="pmid">24025838</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emiliano</surname><given-names>A. B.</given-names></name><name><surname>Cruz</surname><given-names>T.</given-names></name><name><surname>Pannoni</surname><given-names>V.</given-names></name><name><surname>Fudge</surname><given-names>J. L.</given-names></name></person-group> (<year>2007</year>). <article-title>The interface of oxytocin-labeled cells and serotonin transporter-containing fibers in the primate hypothalamus: a substrate for SSRI's therapeutic effects?</article-title>
<source>Neuropsychopharmacology</source>
<volume>32</volume>, <fpage>977</fpage>&#x02013;<lpage>988</lpage>. <pub-id pub-id-type="doi">10.1038/sj.npp.1301206</pub-id><?supplied-pmid 17035935?><pub-id pub-id-type="pmid">17035935</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feldman</surname><given-names>R.</given-names></name></person-group> (<year>2012</year>). <article-title>Oxytocin and social affiliation in humans</article-title>. <source>Horm. Behav</source>. <volume>61</volume>, <fpage>380</fpage>&#x02013;<lpage>391</lpage>. <pub-id pub-id-type="doi">10.1016/j.yhbeh.2012.01.008</pub-id><?supplied-pmid 22285934?><pub-id pub-id-type="pmid">22285934</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frijling</surname><given-names>J. L.</given-names></name><name><surname>Van Zuiden</surname><given-names>M.</given-names></name><name><surname>Koch</surname><given-names>S. B.</given-names></name><name><surname>Nawijn</surname><given-names>L.</given-names></name><name><surname>Goslings</surname><given-names>J. C.</given-names></name><name><surname>Luitse</surname><given-names>J. S.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Efficacy of oxytocin administration early after psychotrauma in preventing the development of PTSD: study protocol of a randomized controlled trial</article-title>. <source>BMC Psychiatry</source>
<volume>14</volume>:<fpage>92</fpage>
<pub-id pub-id-type="doi">10.1186/1471-244X-14-92</pub-id><?supplied-pmid 24679046?><pub-id pub-id-type="pmid">24679046</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gordon</surname><given-names>I.</given-names></name><name><surname>Vander Wyk</surname><given-names>B. C.</given-names></name><name><surname>Bennett</surname><given-names>R. H.</given-names></name><name><surname>Cordeaux</surname><given-names>C.</given-names></name><name><surname>Lucas</surname><given-names>M. V.</given-names></name><name><surname>Eilbott</surname><given-names>J. A.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Oxytocin enhances brain function in children with autism</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A</source>. <volume>110</volume>, <fpage>20953</fpage>&#x02013;<lpage>20958</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1312857110</pub-id><?supplied-pmid 24297883?><pub-id pub-id-type="pmid">24297883</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guastella</surname><given-names>A. J.</given-names></name><name><surname>Einfeld</surname><given-names>S. L.</given-names></name><name><surname>Gray</surname><given-names>K. M.</given-names></name><name><surname>Rinehart</surname><given-names>N. J.</given-names></name><name><surname>Tonge</surname><given-names>B. J.</given-names></name><name><surname>Lambert</surname><given-names>T. J.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders</article-title>. <source>Biol. Psychiatry</source>
<volume>67</volume>, <fpage>692</fpage>&#x02013;<lpage>694</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2009.09.020</pub-id><?supplied-pmid 19897177?><pub-id pub-id-type="pmid">19897177</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guastella</surname><given-names>A. J.</given-names></name><name><surname>Gray</surname><given-names>K. M.</given-names></name><name><surname>Rinehart</surname><given-names>N. J.</given-names></name><name><surname>Alvares</surname><given-names>G. A.</given-names></name><name><surname>Tonge</surname><given-names>B. J.</given-names></name><name><surname>Hickie</surname><given-names>I. B.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>The effects of a course of intranasal oxytocin on social behaviors in youth diagnosed with autism spectrum disorders: a randomized controlled trial</article-title>. <source>J. Child Psychol. Psychiatry</source>. [Epub ahead of print]. <pub-id pub-id-type="doi">10.1111/jcpp.12305</pub-id><?supplied-pmid 25087908?><pub-id pub-id-type="pmid">25087908</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guastella</surname><given-names>A. J.</given-names></name><name><surname>Howard</surname><given-names>A. L.</given-names></name><name><surname>Dadds</surname><given-names>M. R.</given-names></name><name><surname>Mitchell</surname><given-names>P.</given-names></name><name><surname>Carson</surname><given-names>D. S.</given-names></name></person-group> (<year>2009</year>). <article-title>A randomised control trial of intranasal oxytocin as an adjunct to exposure therapy for social anxiety disorder</article-title>. <source>J. Psychoneuroendocrinology</source>
<volume>34</volume>, <fpage>917</fpage>&#x02013;<lpage>923</lpage>. <pub-id pub-id-type="doi">10.1016/j.psyneuen.2009.01.005</pub-id><?supplied-pmid 19246160?><pub-id pub-id-type="pmid">19246160</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guastella</surname><given-names>A. J.</given-names></name><name><surname>Macleod</surname><given-names>C.</given-names></name></person-group> (<year>2012</year>). <article-title>A critical review of the influence of oxytocin nasal spray on social cognition in humans: evidence and future directions</article-title>. <source>Horm. Behav</source>. <volume>61</volume>, <fpage>410</fpage>&#x02013;<lpage>418</lpage>. <pub-id pub-id-type="doi">10.1016/j.yhbeh.2012.01.002</pub-id><?supplied-pmid 22265852?><pub-id pub-id-type="pmid">22265852</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hall</surname><given-names>S. S.</given-names></name><name><surname>Lightbody</surname><given-names>A. A.</given-names></name><name><surname>McCarthy</surname><given-names>B. E.</given-names></name><name><surname>Parker</surname><given-names>K. J.</given-names></name><name><surname>Reiss</surname><given-names>A. L.</given-names></name></person-group> (<year>2012</year>). <article-title>Effects of intranasal oxytocin on social anxiety in males with fragile X syndrome</article-title>. <source>Psychoneuroendocrinology</source>
<volume>37</volume>, <fpage>509</fpage>&#x02013;<lpage>518</lpage>. <pub-id pub-id-type="doi">10.1016/j.psyneuen.2011.07.020</pub-id><?supplied-pmid 21862226?><pub-id pub-id-type="pmid">21862226</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heim</surname><given-names>C.</given-names></name><name><surname>Young</surname><given-names>L. J.</given-names></name><name><surname>Newport</surname><given-names>D. J.</given-names></name><name><surname>Mletzko</surname><given-names>T.</given-names></name><name><surname>Miller</surname><given-names>A. H.</given-names></name><name><surname>Nemeroff</surname><given-names>C. B.</given-names></name></person-group> (<year>2009</year>). <article-title>Lower CSF oxytocin concentrations in women with a history of childhood abuse</article-title>. <source>Mol. Psychiatry</source>
<volume>14</volume>, <fpage>954</fpage>&#x02013;<lpage>958</lpage>. <pub-id pub-id-type="doi">10.1038/mp.2008.112</pub-id><?supplied-pmid 18957940?><pub-id pub-id-type="pmid">18957940</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heinrichs</surname><given-names>M.</given-names></name><name><surname>Baumgartner</surname><given-names>T.</given-names></name><name><surname>Kirschbaum</surname><given-names>C.</given-names></name><name><surname>Ehlert</surname><given-names>U.</given-names></name></person-group> (<year>2003</year>). <article-title>Social support and oxytocin interact to suppress cortisol and subjective responses to psychosocial stress</article-title>. <source>Biol. Psychiatry</source>
<volume>54</volume>, <fpage>1389</fpage>&#x02013;<lpage>1398</lpage>. <pub-id pub-id-type="doi">10.1016/S0006-3223(03)00465-7</pub-id><?supplied-pmid 14675803?><pub-id pub-id-type="pmid">14675803</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hendricks</surname><given-names>C. H.</given-names></name><name><surname>Pose</surname><given-names>S. V.</given-names></name></person-group> (<year>1961</year>). <article-title>Intranasal oxytocin in obstetrics</article-title>. <source>JAMA</source>
<volume>175</volume>, <fpage>384</fpage>&#x02013;<lpage>387</lpage>. <pub-id pub-id-type="doi">10.1001/jama.1961.03040050040009</pub-id><?supplied-pmid 13713293?><pub-id pub-id-type="pmid">13713293</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johns</surname><given-names>J. M.</given-names></name><name><surname>Noonan</surname><given-names>L. R.</given-names></name><name><surname>Zimmerman</surname><given-names>L. I.</given-names></name><name><surname>McMillen</surname><given-names>B. A.</given-names></name><name><surname>Means</surname><given-names>L. W.</given-names></name><name><surname>Walker</surname><given-names>C. H.</given-names></name><etal/></person-group> (<year>1998</year>). <article-title>Chronic cocaine treatment alters social/aggressive behavior in Sprague-Dawley rat dams and in their prenatally exposed offspring</article-title>. <source>Ann. N.Y. Acad. Sci</source>. <volume>846</volume>, <fpage>399</fpage>&#x02013;<lpage>404</lpage>. <pub-id pub-id-type="doi">10.1111/j.1749-6632.1998.tb09765.x</pub-id><?supplied-pmid 9668435?><pub-id pub-id-type="pmid">9668435</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>Y. R.</given-names></name><name><surname>Oh</surname><given-names>S. M.</given-names></name><name><surname>Corfield</surname><given-names>F.</given-names></name><name><surname>Jeong</surname><given-names>D. W.</given-names></name><name><surname>Jang</surname><given-names>E. Y.</given-names></name><name><surname>Treasure</surname><given-names>J.</given-names></name></person-group> (<year>2014</year>). <article-title>Intranasal oxytocin lessens the attentional bias to adult negative faces: a double blind within-subject experiment</article-title>. <source>Psychiatry Investig</source>. <volume>11</volume>, <fpage>160</fpage>&#x02013;<lpage>166</lpage>. <pub-id pub-id-type="doi">10.4306/pi.2014.11.2.160</pub-id><?supplied-pmid 24843371?><pub-id pub-id-type="pmid">24843371</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knobloch</surname><given-names>H. S.</given-names></name><name><surname>Charlet</surname><given-names>A.</given-names></name><name><surname>Hoffmann</surname><given-names>L. C.</given-names></name><name><surname>Eliava</surname><given-names>M.</given-names></name><name><surname>Khrulev</surname><given-names>S.</given-names></name><name><surname>Cetin</surname><given-names>A. H.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Evoked axonal oxytocin release in the central amygdala attenuates fear response</article-title>. <source>Neuron</source>
<volume>73</volume>, <fpage>553</fpage>&#x02013;<lpage>566</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2011.11.030</pub-id><?supplied-pmid 22325206?><pub-id pub-id-type="pmid">22325206</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kovacs</surname><given-names>G. L.</given-names></name><name><surname>Sarnyai</surname><given-names>Z.</given-names></name><name><surname>Szabo</surname><given-names>G.</given-names></name></person-group> (<year>1998</year>). <article-title>Oxytocin and addiction: a review</article-title>. <source>Psychoneuroendocrinology</source>
<volume>23</volume>, <fpage>945</fpage>&#x02013;<lpage>962</lpage>. <pub-id pub-id-type="doi">10.1016/S0306-4530(98)00064-X</pub-id><?supplied-pmid 9924746?><pub-id pub-id-type="pmid">9924746</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>H. J.</given-names></name><name><surname>Macbeth</surname><given-names>A. H.</given-names></name><name><surname>Pagani</surname><given-names>J. H.</given-names></name><name><surname>Young</surname><given-names>W. S.</given-names><suffix>3rd.</suffix></name></person-group> (<year>2009</year>). <article-title>Oxytocin: the great facilitator of life</article-title>. <source>Prog. Neurobiol</source>. <volume>88</volume>, <fpage>127</fpage>&#x02013;<lpage>151</lpage>. <pub-id pub-id-type="doi">10.1016/j.pneurobio.2009.04.001</pub-id><?supplied-pmid 19482229?><pub-id pub-id-type="pmid">19482229</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Love</surname><given-names>T. M.</given-names></name></person-group> (<year>2014</year>). <article-title>Oxytocin, motivation and the role of dopamine</article-title>. <source>Pharmacol. Biochem. Behav</source>. <volume>119</volume>, <fpage>49</fpage>&#x02013;<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1016/j.pbb.2013.06.011</pub-id><?supplied-pmid 23850525?><pub-id pub-id-type="pmid">23850525</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGregor</surname><given-names>I. S.</given-names></name><name><surname>Bowen</surname><given-names>M. T.</given-names></name></person-group> (<year>2012</year>). <article-title>Breaking the loop: oxytocin as a potential treatment for drug addiction</article-title>. <source>Horm. Behav</source>. <volume>61</volume>, <fpage>331</fpage>&#x02013;<lpage>339</lpage>. <pub-id pub-id-type="doi">10.1016/j.yhbeh.2011.12.001</pub-id><?supplied-pmid 22198308?><pub-id pub-id-type="pmid">22198308</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyer-Lindenberg</surname><given-names>A.</given-names></name><name><surname>Domes</surname><given-names>G.</given-names></name><name><surname>Kirsch</surname><given-names>P.</given-names></name><name><surname>Heinrichs</surname><given-names>M.</given-names></name></person-group> (<year>2011</year>). <article-title>Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine</article-title>. <source>Nat. Rev. Neurosci</source>. <volume>12</volume>, <fpage>524</fpage>&#x02013;<lpage>538</lpage>. <pub-id pub-id-type="doi">10.1038/nrn3044</pub-id><?supplied-pmid 21852800?><pub-id pub-id-type="pmid">21852800</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>G.</given-names></name></person-group> (<year>2013</year>). <article-title>Neuroscience. The promise and perils of oxytocin</article-title>. <source>Science</source>
<volume>339</volume>, <fpage>267</fpage>&#x02013;<lpage>269</lpage>. <pub-id pub-id-type="doi">10.1126/science.339.6117.267</pub-id><?supplied-pmid 23329028?><pub-id pub-id-type="pmid">23329028</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>M.</given-names></name><name><surname>Bales</surname><given-names>K. L.</given-names></name><name><surname>Taylor</surname><given-names>S. L.</given-names></name><name><surname>Yoon</surname><given-names>J.</given-names></name><name><surname>Hostetler</surname><given-names>C. M.</given-names></name><name><surname>Carter</surname><given-names>C. S.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Oxytocin and vasopressin in children and adolescents with autism spectrum disorders: sex differences and associations with symptoms</article-title>. <source>Autism Res</source>. <volume>6</volume>, <fpage>91</fpage>&#x02013;<lpage>102</lpage>. <pub-id pub-id-type="doi">10.1002/aur.1270</pub-id><?supplied-pmid 23413037?><pub-id pub-id-type="pmid">23413037</pub-id></mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olff</surname><given-names>M.</given-names></name></person-group> (<year>2012</year>). <article-title>Bonding after trauma: on the role of social support and the oxytocin system in traumatic stress</article-title>. <source>Eur. J. Psychotraumatol</source>. <volume>3</volume>:<fpage>18597</fpage>
<pub-id pub-id-type="doi">10.3402/ejpt.v3i0.18597</pub-id><?supplied-pmid 22893838?><pub-id pub-id-type="pmid">22893838</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Opacka-Juffry</surname><given-names>J.</given-names></name><name><surname>Mohiyeddini</surname><given-names>C.</given-names></name></person-group> (<year>2012</year>). <article-title>Experience of stress in childhood negatively correlates with plasma oxytocin concentration in adult men</article-title>. <source>Stress</source>
<volume>15</volume>, <fpage>1</fpage>&#x02013;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.3109/10253890.2011.560309</pub-id><?supplied-pmid 21682649?><pub-id pub-id-type="pmid">21682649</pub-id></mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oreland</surname><given-names>S.</given-names></name><name><surname>Gustafsson-Ericson</surname><given-names>L.</given-names></name><name><surname>Nylander</surname><given-names>I.</given-names></name></person-group> (<year>2010</year>). <article-title>Short- and long-term consequences of different early environmental conditions on central immunoreactive oxytocin and arginine vasopressin levels in male rats</article-title>. <source>Neuropeptides</source>
<volume>44</volume>, <fpage>391</fpage>&#x02013;<lpage>398</lpage>. <pub-id pub-id-type="doi">10.1016/j.npep.2010.06.001</pub-id><?supplied-pmid 20591479?><pub-id pub-id-type="pmid">20591479</pub-id></mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parker</surname><given-names>K. J.</given-names></name><name><surname>Buckmaster</surname><given-names>C. L.</given-names></name><name><surname>Schatzberg</surname><given-names>A. F.</given-names></name><name><surname>Lyons</surname><given-names>D. M.</given-names></name></person-group> (<year>2005</year>). <article-title>Intranasal oxytocin administration attenuates the ACTH stress response in monkeys</article-title>. <source>Psychoneuroendocrinology</source>
<volume>30</volume>, <fpage>924</fpage>&#x02013;<lpage>929</lpage>. <pub-id pub-id-type="doi">10.1016/j.psyneuen.2005.04.002</pub-id><?supplied-pmid 15946803?><pub-id pub-id-type="pmid">15946803</pub-id></mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pedersen</surname><given-names>C. A.</given-names></name><name><surname>Smedley</surname><given-names>K. L.</given-names></name><name><surname>Leserman</surname><given-names>J.</given-names></name><name><surname>Jarskog</surname><given-names>L. F.</given-names></name><name><surname>Rau</surname><given-names>S. W.</given-names></name><name><surname>Kampov-Polevoi</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Intranasal oxytocin blocks alcohol withdrawal in human subjects</article-title>. <source>Alcohol. Clin. Exp. Res</source>. <volume>37</volume>, <fpage>484</fpage>&#x02013;<lpage>489</lpage>. <pub-id pub-id-type="doi">10.1111/j.1530-0277.2012.01958.x</pub-id><?supplied-pmid 23025690?><pub-id pub-id-type="pmid">23025690</pub-id></mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pitman</surname><given-names>R. K.</given-names></name><name><surname>Orr</surname><given-names>S. P.</given-names></name><name><surname>Lasko</surname><given-names>N. B.</given-names></name></person-group> (<year>1993</year>). <article-title>Effects of intranasal vasopressin and oxytocin on physiologic responding during personal combat imagery in Vietnam veterans with posttraumatic stress disorder</article-title>. <source>Psychiatry Res</source>. <volume>48</volume>, <fpage>107</fpage>&#x02013;<lpage>117</lpage>. <pub-id pub-id-type="doi">10.1016/0165-1781(93)90035-F</pub-id><?supplied-pmid 8416021?><pub-id pub-id-type="pmid">8416021</pub-id></mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Preti</surname><given-names>A.</given-names></name><name><surname>Melis</surname><given-names>M.</given-names></name><name><surname>Siddi</surname><given-names>S.</given-names></name><name><surname>Vellante</surname><given-names>M.</given-names></name><name><surname>Doneddu</surname><given-names>G.</given-names></name><name><surname>Fadda</surname><given-names>R.</given-names></name></person-group> (<year>2014</year>). <article-title>Oxytocin and autism: a systematic review of randomized controlled trials</article-title>. <source>J. Child Adolesc. Psychopharmacol</source>. <volume>24</volume>, <fpage>54</fpage>&#x02013;<lpage>68</lpage>. <pub-id pub-id-type="doi">10.1089/cap.2013.0040</pub-id><?supplied-pmid 24679173?><pub-id pub-id-type="pmid">24679173</pub-id></mixed-citation></ref><ref id="B56"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rault</surname><given-names>J. L.</given-names></name><name><surname>Carter</surname><given-names>C. S.</given-names></name><name><surname>Garner</surname><given-names>J. P.</given-names></name><name><surname>Marchant-Forde</surname><given-names>J. N.</given-names></name><name><surname>Richert</surname><given-names>B. T.</given-names></name><name><surname>Lay</surname><given-names>D. C.</given-names><suffix>Jr.</suffix></name></person-group> (<year>2013</year>). <article-title>Repeated intranasal oxytocin administration in early life dysregulates the HPA axis and alters social behavior</article-title>. <source>Physiol. Behav</source>. <volume>112&#x02013;113</volume>, <fpage>40</fpage>&#x02013;<lpage>48</lpage>. <pub-id pub-id-type="doi">10.1016/j.physbeh.2013.02.007</pub-id><?supplied-pmid 23481917?><pub-id pub-id-type="pmid">23481917</pub-id></mixed-citation></ref><ref id="B57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rilling</surname><given-names>J. K.</given-names></name><name><surname>Demarco</surname><given-names>A. C.</given-names></name><name><surname>Hackett</surname><given-names>P. D.</given-names></name><name><surname>Thompson</surname><given-names>R.</given-names></name><name><surname>Ditzen</surname><given-names>B.</given-names></name><name><surname>Patel</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Effects of intranasal oxytocin and vasopressin on cooperative behavior and associated brain activity in men</article-title>. <source>Psychoneuroendocrinology</source>
<volume>37</volume>, <fpage>447</fpage>&#x02013;<lpage>461</lpage>. <pub-id pub-id-type="doi">10.1016/j.psyneuen.2011.07.013</pub-id><?supplied-pmid 21840129?><pub-id pub-id-type="pmid">21840129</pub-id></mixed-citation></ref><ref id="B58"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarnyai</surname><given-names>Z.</given-names></name><name><surname>Kovacs</surname><given-names>G. L.</given-names></name></person-group> (<year>2014</year>). <article-title>Oxytocin in learning and addiction: from early discoveries to the present</article-title>. <source>Pharmacol. Biochem. Behav</source>. <volume>119</volume>, <fpage>3</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.pbb.2013.11.019</pub-id><?supplied-pmid 24280016?><pub-id pub-id-type="pmid">24280016</pub-id></mixed-citation></ref><ref id="B59"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simpson</surname><given-names>E. A.</given-names></name><name><surname>Sclafani</surname><given-names>V.</given-names></name><name><surname>Paukner</surname><given-names>A.</given-names></name><name><surname>Hamel</surname><given-names>A. F.</given-names></name><name><surname>Novak</surname><given-names>M. A.</given-names></name><name><surname>Meyer</surname><given-names>J. S.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Inhaled oxytocin increases positive social behaviors in newborn macaques</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A</source>. <volume>111</volume>, <fpage>6922</fpage>&#x02013;<lpage>6927</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1402471111</pub-id><?supplied-pmid 24778211?><pub-id pub-id-type="pmid">24778211</pub-id></mixed-citation></ref><ref id="B60"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suraev</surname><given-names>A. S.</given-names></name><name><surname>Bowen</surname><given-names>M. T.</given-names></name><name><surname>Ali</surname><given-names>S. O.</given-names></name><name><surname>Hicks</surname><given-names>C.</given-names></name><name><surname>Ramos</surname><given-names>L.</given-names></name><name><surname>McGregor</surname><given-names>I. S.</given-names></name></person-group> (<year>2014</year>). <article-title>Adolescent exposure to oxytocin, but not the selective oxytocin receptor agonist TGOT, increases social behavior and plasma oxytocin in adulthood</article-title>. <source>Horm. Behav</source>. <volume>65</volume>, <fpage>488</fpage>&#x02013;<lpage>496</lpage>. <pub-id pub-id-type="doi">10.1016/j.yhbeh.2014.03.002</pub-id><?supplied-pmid 24631584?><pub-id pub-id-type="pmid">24631584</pub-id></mixed-citation></ref><ref id="B61"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tachibana</surname><given-names>M.</given-names></name><name><surname>Kagitani-Shimono</surname><given-names>K.</given-names></name><name><surname>Mohri</surname><given-names>I.</given-names></name><name><surname>Yamamoto</surname><given-names>T.</given-names></name><name><surname>Sanefuji</surname><given-names>W.</given-names></name><name><surname>Nakamura</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Long-term administration of intranasal oxytocin is a safe and promising therapy for early adolescent boys with autism spectrum disorders</article-title>. <source>J. Child Adolesc. Psychopharmacol</source>. <volume>23</volume>, <fpage>123</fpage>&#x02013;<lpage>127</lpage>. <pub-id pub-id-type="doi">10.1089/cap.2012.0048</pub-id><?supplied-pmid 23480321?><pub-id pub-id-type="pmid">23480321</pub-id></mixed-citation></ref><ref id="B62"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tops</surname><given-names>M.</given-names></name><name><surname>Koole</surname><given-names>S. L.</given-names></name><name><surname>IJzerman</surname><given-names>H.</given-names></name><name><surname>Buisman-Pijlman</surname><given-names>F. T.</given-names></name></person-group> (<year>2014</year>). <article-title>Why social attachment and oxytocin protect against addiction and stress: insights from the dynamics between ventral and dorsal corticostriatal systems</article-title>. <source>Pharmacol. Biochem. Behav</source>. <volume>119</volume>, <fpage>39</fpage>&#x02013;<lpage>48</lpage>. <pub-id pub-id-type="doi">10.1016/j.pbb.2013.07.015</pub-id><?supplied-pmid 23916423?><pub-id pub-id-type="pmid">23916423</pub-id></mixed-citation></ref><ref id="B63"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veening</surname><given-names>J. G.</given-names></name><name><surname>Olivier</surname><given-names>B.</given-names></name></person-group> (<year>2013</year>). <article-title>Intranasal administration of oxytocin: behavioral and clinical effects, a review</article-title>. <source>Neurosci. Biobehav. Rev</source>. <volume>37</volume>, <fpage>1445</fpage>&#x02013;<lpage>1465</lpage>. <pub-id pub-id-type="doi">10.1016/j.neubiorev.2013.04.012</pub-id><?supplied-pmid 23648680?><pub-id pub-id-type="pmid">23648680</pub-id></mixed-citation></ref><ref id="B64"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>S. K.</given-names></name><name><surname>Johns</surname><given-names>J. M.</given-names></name></person-group> (<year>2014</year>). <article-title>Prenatal and gestational cocaine exposure: effects on the oxytocin system and social behavior with implications for addiction</article-title>. <source>Pharmacol. Biochem. Behav</source>. <volume>119</volume>, <fpage>10</fpage>&#x02013;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1016/j.pbb.2013.07.004</pub-id><?supplied-pmid 23880214?><pub-id pub-id-type="pmid">23880214</pub-id></mixed-citation></ref><ref id="B65"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zanos</surname><given-names>P.</given-names></name><name><surname>Wright</surname><given-names>S. R.</given-names></name><name><surname>Georgiou</surname><given-names>P.</given-names></name><name><surname>Yoo</surname><given-names>J. H.</given-names></name><name><surname>Ledent</surname><given-names>C.</given-names></name><name><surname>Hourani</surname><given-names>S. M.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Chronic methamphetamine treatment induces oxytocin receptor up-regulation in the amygdala and hypothalamus via an adenosine A2A receptor-independent mechanism</article-title>. <source>Pharmacol. Biochem. Behav</source>. <volume>119</volume>, <fpage>72</fpage>&#x02013;<lpage>79</lpage>. <pub-id pub-id-type="doi">10.1016/j.pbb.2013.05.009</pub-id><?supplied-pmid 23680573?><pub-id pub-id-type="pmid">23680573</pub-id></mixed-citation></ref></ref-list></back></article>